Burden of neurodegenerative diseases: Parkinson's disease ICD10
Metadata
- Coding system
- ICD-10
- Coding system release
- combined_20260909105914_47430d19
- Organisation
- University of Bristol
- Codelist ID
- bristol/burden-of-neurodegenerative-diseases-parkinsons-disease
- Version ID
- 74f665a6
- Number of codes included
- 2
About
Description
The ICD-10 code lists were created by defining the disease of interest by a clinician, then searching relevant codes in the ICD-10 code browser.
Prevalent cases of neurodegenerative disease with an established diagnosis.
NB. This codelist does not include parkinsonism + disorders (multi-system atrophy or progressive supranuclear palsy). These codelists have been developed separately and can be used in conjunction with this one.
Methodology
Context
The codelist is for use in a neurodegenerative disease burden study (Bristol/ Edinburgh/ Cambridge); and captures prevalent cases with an established diagnosis. The codelists were developed for neurodegenerative diseases of interest: Dementia, Parkinson’s Disease, Parkinson’s-plus syndromes, Motor Neurone Disease. For the diseases of interest, we reviewed established codelists (e.g. QoF for SNOMED terms), and created any required codelists using diagnostic terms as search criteria. ICD-10 browser was consulted for hierarchies and additional terms. For Dementia, we developed codelists for ‘Unspecified Dementia’ and ‘Other Specified Dementia’ which included rarer or less commonly captured causes such as Dementia due to Huntington’s disease.
Inclusion/exclusion criteria
Codes indicative of an established diagnosis.
Borderline cases
MSA and PSP are excluded and separate code lists are created. Secondary parkinsonism is excluded as does not usually represent the typical primary neurodegenerative disorder.
Sensitivity vs specificity
The primary aim was specificity. We included codes representing a clinical diagnosis of the condition of interest, rather than codes based solely on symptoms or clinical features.
Additional information
Proposed by W Whiteley & S Sarepalli. Reviewed and modified by A Tamborska & W Shi.
References
Signed off by
- Arina Tamborska, (Sept. 11, 2026)
Codelists are developed by a broad community of users for individual study purposes, which may or may not meet the needs of other studies. They should not be thought of as universal definitions of a particular condition.
We don't offer any guarantees about what they do or don't identify. Users should carefully check that any codelist meets their needs, and seek clinical input where appropriate.
| code | term |
|---|---|
| F023 | Dementia in Parkinson disease |
| G20 | Parkinson disease |
This page shows the search terms that were used to build the codelist. Concepts that match the search terms, but which were excluded, are in faint grey.
parkinson
Included 2 out of 67 matching concepts.
Show matching concepts
-
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified (
X41) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Farm (
X417) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Home (
X410) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Industrial and construction area (
X416) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Other specified places (
X418) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Residential institution (
X411) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : School, other institution and public administrative area (
X412) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Sports and athletics area (
X413) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Street and highway (
X414) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Trade and service area (
X415) -
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Unspecified place (
X419) -
Antiepileptics and antiparkinsonism drugs (
Y46) -
Antiparkinsonism drugs (
Y467) -
Antispasticity drugs (
Y468) -
Dementia in Parkinson disease (
F023) -
Deoxybarbiturates (
Y463) -
Hydantoin derivatives (
Y462) -
Iminostilbenes (
Y464) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified (
X61) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Farm (
X617) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Home (
X610) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Industrial and construction area (
X616) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Other specified places (
X618) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Residential institution (
X611) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : School, other institution and public administrative area (
X612) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Sports and athletics area (
X613) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Street and highway (
X614) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Trade and service area (
X615) -
Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified : Unspecified place (
X619) -
Malignant neuroleptic syndrome (
G210) -
Multiple system atrophy, parkinsonian type [MSA-P] (
G232) -
Other and unspecified antiepileptics (
Y466) -
Other drug-induced secondary parkinsonism (
G211) -
Other secondary parkinsonism (
G218) -
Oxazolidinediones (
Y461) -
Parkinson disease (
G20) -
Parkinsonism in diseases classified elsewhere (
G22) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent (
Y11) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Farm (
Y117) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Home (
Y110) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Industrial and construction area (
Y116) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Other specified places (
Y118) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Residential institution (
Y111) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : School, other institution and public administrative area (
Y112) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Sports and athletics area (
Y113) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Street and highway (
Y114) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Trade and service area (
Y115) -
Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent : Unspecified place (
Y119) -
Poisoning by antiepileptic, sedative-hypnotic and antiparkinsonism drugs (
T42) -
Poisoning: Antiepileptic and sedative-hypnotic drugs, unspecified (
T427) -
Poisoning: Antiparkinsonism drugs and other central muscle-tone depressants (
T428) -
Poisoning: Barbiturates (
T423) -
Poisoning: Benzodiazepines (
T424) -
Poisoning: Hydantoin derivatives (
T420) -
Poisoning: Iminostilbenes (
T421) -
Poisoning: Mixed antiepileptics, not elsewhere classified (
T425) -
Poisoning: Other antiepileptic and sedative-hypnotic drugs (
T426) -
Poisoning: Succinimides and oxazolidinediones (
T422) -
Postencephalitic parkinsonism (
G213) -
Pre-excitation syndrome (
I456) -
Secondary parkinsonism (
G21) -
Secondary parkinsonism due to other external agents (
G212) -
Secondary parkinsonism, unspecified (
G219) -
Succinimides (
Y460) -
Symptomatic neurosyphilis (
A521) -
Valproic acid (
Y465) -
Vascular parkinsonism (
G214)